Teva, Glenmark to pay $255 million to resolve DOJ price-fixing claims

Teva Pharmaceuticals and Glenmark Pharmaceuticals reached deferred prosecution agreements with the Department of Justice to resolve antitrust claims over a generic drug price-fixing cartel....

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@mlex.com

Try FTCWatch FREE for 45 days

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch

Current Issue: 1056
Next Issue: Oct 3, 2023

Browse Archives

In this Issue:

Meta and FTC, in charged written exchange over 2020 privacy settlement, swap barbs over ‘unlawful’ behavior
People
Calendar
‘Antidomination’ should replace consumer sovereignty framework, professor argues
On the Shelf: How FDR expanded business regulation and weakened the FTC
Toy manufacturers split with privacy advocates on parental consent proposal
Intuit deceived consumers about ‘free’ tax services, FTC judge rules
Funeral providers, consumer advocates debate online posting of prices
Healthcare staffing executive indicted over fixing nurses’ wages
Holyoak, Ferguson could change FTC dynamics but face steep learning curve
Asphalt paving firm, president plead guilty to bid-rigging charges
Elite colleges embroiled in antitrust litigation as lawmaker pushes for FTC probe
NLRB sending cases on noncompetes, gig work to FTC, Abruzzo says
Neil Averitt commentary: Insulin cases need a sharper focus
Calendar
Constitutional defenses in Illumina case may help FTC delay ‘generational’ increase in skepticism of agencies
Neil Averitt commentary: What should we be asking from the economics profession?
Beware weather-related scams, FTC says
FTC studies teamwork with AGs
Google’s adtech case previews growing discovery headaches for government enforcers

RSS Feed